Longeveron Inc
Company Profile
Business description
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Contact
1951 NW 7th Avenue
Suite 520
MiamiFL33136
USAT: +1 305 909-0840
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.20 | 71.40 | -0.80% |
| CAC 40 | 7,692.13 | 77.08 | -0.99% |
| DAX 40 | 24,830.26 | 274.10 | -1.09% |
| Dow JONES (US) | 51,179.87 | 341.41 | -0.66% |
| FTSE 100 | 10,407.17 | 51.33 | -0.49% |
| HKSE | 23,785.79 | 344.71 | -1.43% |
| NASDAQ | 27,538.69 | 61.20 | -0.22% |
| Nikkei 225 | 69,042.11 | 993.60 | -1.42% |
| NZX 50 Index | 13,691.85 | 7.81 | 0.06% |
| S&P 500 | 7,801.77 | 17.16 | -0.22% |
| S&P/ASX 200 | 8,660.90 | 66.80 | -0.77% |
| SSE Composite Index | 3,811.90 | 30.29 | -0.79% |